

Edmund K Moon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5185048/publications.pdf>

Version: 2024-02-01

32
papers

3,769
citations

331670

21
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

5309
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100301.	1.1	7
2	Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. <i>Molecular Therapy</i> , 2021, 29, 658-670.	8.2	8
3	Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. <i>Oncolmmunology</i> , 2021, 10, 1873607.	4.6	20
4	A human CD137 $\tilde{\text{A}}$ –PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. <i>Nature Communications</i> , 2021, 12, 4445.	12.8	54
5	CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. <i>Cells</i> , 2021, 10, 2334.	4.1	7
6	An NK-like CAR T $\tilde{\text{A}}$ cell transition in CAR T $\tilde{\text{A}}$ cell dysfunction. <i>Cell</i> , 2021, 184, 6081-6100.e26.	28.9	160
7	Lactate Limits T Cell Proliferation via the NAD(H) Redox State. <i>Cell Reports</i> , 2020, 33, 108500.	6.4	135
8	Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In $\tilde{\text{A}}$ Vitro and In $\tilde{\text{A}}$ Vivo. <i>Molecular Therapy</i> , 2020, 28, 1600-1613.	8.2	45
9	Photodynamic Therapy and Immune Checkpoint Blockade ^{&lt;sup>} . <i>Photochemistry and Photobiology</i> , 2020, 96, 954-961.	2.5	54
10	Neoadjuvant endobronchial delivery of gene mediated cytotoxic immunotherapy (GMCI) for non-small cell lung cancer (NSCLC): Safety and immunologic activity.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9050-9050.	1.6	0
11	Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2019, 8, e1638211.	4.6	33
12	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. <i>Molecular Therapy</i> , 2019, 27, 1919-1929.	8.2	220
13	Loss of cells expressing fibroblast activation protein has variable effects in models of TGF- $\tilde{\text{I}}$ ² and chronic bleomycin-induced fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L271-L282.	2.9	25
14	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non $\tilde{\text{A}}$ Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 896-909.	3.4	64
15	$\tilde{\text{I}}$ ³ T Cells in Lung Cancer Malignant Pleural Effusion: Friend? Foe?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 130-131.	2.9	4
16	Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. <i>Oncolmmunology</i> , 2018, 7, e1395997.	4.6	108
17	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1248-1260.	3.2	15
18	Development of novel avenues to overcome challenges facing CAR T cells. <i>Translational Research</i> , 2017, 187, 22-31.	5.0	4

#	ARTICLE	IF	CITATIONS
19	CAR T Cell Therapy for Solid Tumors. Annual Review of Medicine, 2017, 68, 139-152.	12.2	600
20	Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e450-e458.	3.8	35
21	Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. Frontiers in Cell and Developmental Biology, 2016, 4, 108.	3.7	45
22	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer Cell, 2016, 30, 120-135.	16.8	311
23	Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunology Research, 2016, 4, 541-551.	3.4	153
24	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Research, 2016, 76, 1578-1590.	0.9	411
25	Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN± Combined with Chemotherapy. Clinical Cancer Research, 2016, 22, 3791-3800.	7.0	77
26	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clinical Cancer Research, 2016, 22, 436-447.	7.0	107
27	Chimeric antigen receptor T-cell therapy for solid tumors. Molecular Therapy - Oncolytics, 2016, 3, 16006.	4.4	191
28	Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma. Immunology Letters, 2015, 166, 28-35.	2.5	3
29	Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunology Research, 2015, 3, 815-826.	3.4	87
30	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. Clinical Cancer Research, 2014, 20, 4262-4273.	7.0	339
31	Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road. OncoImmunology, 2013, 2, e26492.	4.6	6
32	Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. Clinical Cancer Research, 2011, 17, 4719-4730.	7.0	441